Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return.
As of today, Rigel Pharmaceuticals's Shareholder Yield % was 1.23%.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
Rigel Pharmaceuticals Shareholder Yield % Related Terms
Rigel Pharmaceuticals Shareholder Yield % Historical Data
* Premium members only.
The historical data trend for Rigel Pharmaceuticals's Shareholder Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:RI2 vs CADL, IMMX, AURA: Shareholder Yield % Comparison
For the Biotechnology subindustry, Rigel Pharmaceuticals's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rigel Pharmaceuticals Shareholder Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rigel Pharmaceuticals's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where Rigel Pharmaceuticals's Shareholder Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
Rigel Pharmaceuticals (FRA:RI2) has a Shareholder Yield % of 1.23% as of Mar. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Rigel Pharmaceuticals and its competitors. According to the industry distribution chart, Rigel Pharmaceuticals ranks #265 out of 1298 companies in the Biotechnology industry, placing it in the top 20.4%.
Is Rigel Pharmaceuticals' Shareholder Yield % too high?
Rigel Pharmaceuticals' current Shareholder Yield % is 1.23%. Based on the distribution chart, Rigel Pharmaceuticals ranks #265 out of 1298 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Rigel Pharmaceuticals has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Rigel Pharmaceuticals' Shareholder Yield % compare to CADL and IMMX?
According to the Biotechnology industry distribution chart, Rigel Pharmaceuticals ranks #265 out of 1298 companies for Shareholder Yield %. This places Rigel Pharmaceuticals in the top 20% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Biotechnology company?
A good Shareholder Yield % depends on the Biotechnology industry context. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Rigel Pharmaceuticals and its competitors. Rigel Pharmaceuticals's current Shareholder Yield % is 1.23%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rigel Pharmaceuticals stock overvalued right now?
Rigel Pharmaceuticals (FRA:RI2) has a current Shareholder Yield % of 1.23%. The stock's GF Value™ is €24.33, compared to a current price of €33.59 — trading 38.1% above its estimated fair value. The current Shareholder Yield % is 1.23%. Rigel Pharmaceuticals' overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Rigel Pharmaceuticals (FRA:RI2), the current Shareholder Yield % is 1.23% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rigel Pharmaceuticals (FRA:RI2) Overvalued in 2026?
Based on GuruFocus' analysis, Rigel Pharmaceuticals stock appears to be overvalued.
The current stock price of €33.59 is trading 38.1% above its estimated GF Value™ of €24.33.
Key valuation signals for FRA:RI2:
Shareholder Yield %: 1.23%
GF Value™: €24.33 vs. price of €33.59 (38.1% above fair value)
No single metric tells the full story. See the FRA:RI2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
76GF Score
Get the complete analysis for FRA:RI2
Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:RI2 has been successfully added to your 
